Literature DB >> 17681634

Targeted delivery to the nucleus.

Colin W Pouton1, Kylie M Wagstaff, Daniela M Roth, Gregory W Moseley, David A Jans.   

Abstract

Macromolecules and supramolecular complexes are frequently required to enter and exit the nucleus during normal cell function, but access is restricted and exchange to and from the nucleus is tightly controlled. We describe the mechanisms which regulate nuclear import of endogenous molecules and indicate how viruses exploit these mechanisms during their life cycle. Opportunities exist to make use of natural pathways for delivery of therapeutic entities, in particular to develop safe and effective methods for gene therapy, although past attempts to design non-viral nuclear delivery systems have met with limited success. To increase the likelihood of success scientists will need an appreciation of the mechanisms by which viruses deliver their genomes to the nucleus, and will need a commitment to control the architecture of non-viral delivery systems at the molecular level. Effective delivery systems will require several attributes to facilitate endosomal escape, microtubular transport and uptake through the nuclear pore complex. The published literature provides a strong foundation for design of nuclear targeting systems. The challenge faced by delivery scientists is to assemble a system which is as effective as, for example, the adenovirus but which lacks its immunogenicity. This article reviews the relevant literature and indicates key areas for future research.

Mesh:

Substances:

Year:  2007        PMID: 17681634     DOI: 10.1016/j.addr.2007.06.010

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  43 in total

1.  The ORF012 gene of Marek's disease virus type 1 produces a spliced transcript and encodes a novel nuclear phosphoprotein essential for virus growth.

Authors:  Timo Schippers; Keith Jarosinski; Nikolaus Osterrieder
Journal:  J Virol       Date:  2014-11-12       Impact factor: 5.103

Review 2.  Strategies in the design of nanoparticles for therapeutic applications.

Authors:  Robby A Petros; Joseph M DeSimone
Journal:  Nat Rev Drug Discov       Date:  2010-07-09       Impact factor: 84.694

Review 3.  Gene electrotransfer: from biophysical mechanisms to in vivo applications : Part 1- Biophysical mechanisms.

Authors:  Jean-Michel Escoffre; Chloé Mauroy; Thomas Portet; Luc Wasungu; Chrystelle Rosazza; Yoann Gilbart; Laetitia Mallet; Elisabeth Bellard; Muriel Golzio; Marie-Pierre Rols; Justin Teissié
Journal:  Biophys Rev       Date:  2009-11-17

4.  Novel pentablock copolymers for selective gene delivery to cancer cells.

Authors:  Bingqi Zhang; Mathumai Kanapathipillai; Paul Bisso; Surya Mallapragada
Journal:  Pharm Res       Date:  2009-01-14       Impact factor: 4.200

5.  Nuclear import of the varicella-zoster virus latency-associated protein ORF63 in primary neurons requires expression of the lytic protein ORF61 and occurs in a proteasome-dependent manner.

Authors:  Matthew S Walters; Christos A Kyratsous; Shilin Wan; Saul Silverstein
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

6.  Nuclear entry of activated MAPK is restricted in primary ovarian and mammary epithelial cells.

Authors:  Elizabeth R Smith; Kathy Qi Cai; Jennifer L Smedberg; Melina M Ribeiro; Malgorzata E Rula; Carolyn Slater; Andrew K Godwin; Xiang-Xi Xu
Journal:  PLoS One       Date:  2010-02-18       Impact factor: 3.240

7.  E. coli expression of a soluble, active single-chain antibody variable fragment containing a nuclear localization signal.

Authors:  Hairong Xiong; Shuyi Li; Zhanqiu Yang; Richard R Burgess; William S Dynan
Journal:  Protein Expr Purif       Date:  2009-03-10       Impact factor: 1.650

8.  A novel cationic lipid with intrinsic antitumor activity to facilitate gene therapy of TRAIL DNA.

Authors:  Cong Luo; Lei Miao; Yi Zhao; Sara Musetti; Yuhua Wang; Kai Shi; Leaf Huang
Journal:  Biomaterials       Date:  2016-06-16       Impact factor: 12.479

9.  Transportin mediates nuclear entry of DNA in vertebrate systems.

Authors:  Aurelie Lachish-Zalait; Corine K Lau; Boris Fichtman; Ella Zimmerman; Amnon Harel; Michelle R Gaylord; Douglass J Forbes; Michael Elbaum
Journal:  Traffic       Date:  2009-10       Impact factor: 6.215

10.  PDGF-B gene therapy accelerates bone engineering and oral implant osseointegration.

Authors:  P-C Chang; Y-J Seol; J A Cirelli; G Pellegrini; Q Jin; L M Franco; S A Goldstein; L A Chandler; B Sosnowski; W V Giannobile
Journal:  Gene Ther       Date:  2009-09-10       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.